EDP 938

Drug Profile

EDP 938

Alternative Names: EDP 938; EP 023938

Latest Information Update: 14 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Enanta Pharmaceuticals
  • Developer Enanta Pharmaceuticals; Pharmaceutical Research Associates
  • Class Antivirals
  • Mechanism of Action Viral fusion protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Respiratory syncytial virus infections

Most Recent Events

  • 08 May 2018 EDP 938 receives Fast Track designation for Respiratory syncytial virus infections [PO] (In volunteers) in USA
  • 05 Jan 2018 Enanta plans a phase II proof-of-concept challenge trial for Respiratory syncytial virus infections in USA in fourth quarter of 2018
  • 07 Dec 2017 Phase-I clinical trials in Respiratory syncytial virus infections (In volunteers) in USA (PO) (NCT03384823)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top